Welcome to Genomics Now, a podcast series where you can learn how genomics is developing in England's NHS. This podcast series is recorded in 2024 and is part of the North Thames Genomic Medicine Service's (NTGMS) educational toolkit.

In each bite-sized episode, we explore what is changing in genomics. We answer the questions on genomics we've been asked by different healthcare professionals, discuss the ways genomics may impact various healthcare roles, and how genomics can be used to improve patient care successfully.

In this final episode of the NTGMS liquid biopsy podcast series, Dr. Shazia Mahamdallie welcomes Gini as her co-host, a Trustee for EGFR Positive UK. Today, they are joined by Mark and Janet who have lived-experience of biopsy testing for lung cancer.

Mark was diagnosed 12 years ago with stage two lung cancer, today he shares his journey from initial symptoms to the groundbreaking liquid biopsy that revealed a genetic change leading to successful targeted treatment.

Janet recounts her recent diagnosis and the symptoms that led her to participate in the NHS's lung cancer pilot for liquid biopsy testing, and that led to her swift treatment turnaround.

Join us as we explore the critical role of liquid biopsies in lung cancer treatment and the profound impact this test the NHS is piloting can have on patients' lives.

For more resources and updates on genomic-based clinical developments and research, visit the North Thames Genomic Medicine Service website. If you enjoyed this episode, share your thoughts and spread the word on social media by tagging the North Thames Genomic Medicine Service.

Welcome to Genomics Now, a podcast series where you can learn how genomics is developing in England's NHS. This podcast series is recorded in 2024 and is part of the North Thames Genomic Medicine Services Educational Toolkit. In each bite-sized episode, we explore what is changing in genomics. We answer the questions on genomics we've been asked by different healthcare professionals, discuss how genomics may impact various healthcare roles, and examine how genomics can be used to successfully improve patient care.

In today’s episode, we delve into the clinician's perspective on NHS England's liquid biopsy circulating tumour DNA pilot. Hosted by Dr. Shazia Mahamdallie, this episode features Dr. Alistair Greystoke, a Professor of Oncology, and Dr. William Ricketts, a Consultant chest physician. They discuss the integration and impact of liquid biopsy testing on lung cancer diagnosis and patient care.

Join us and learn about the practical tips, patient benefits, and logistical challenges encountered during the pilot, as well as the promising future applications of liquid biopsy testing in diagnostics and treatment monitoring. Tune in for an engaging and informative discussion that highlights the potential of genomics to change how we deliver healthcare.

For more resources and updates on genomic-based clinical developments and research, visit the North Thames Genomic Medicine Service website. If you enjoyed this episode, share your thoughts and spread the word on social media by tagging the North Thames Genomic Medicine Service.

Welcome to Genomics Now, a podcast series where you can learn how genomics is developing in England's NHS. This podcast series is recorded in 2024 and is part of the North Thames Genomic Medicine Service's educational toolkit.

In each bite-sized episode, we explore what is changing in genomics. We answer the questions on genomics we've been asked by different healthcare professionals, discuss the ways genomics may impact various healthcare roles, and how genomics can be used to improve patient care successfully.

In this episode, Dr. Shazia Mahamdallie is joined by Stephen Kelly, UK Medical Director at Guardant Health, and Dr. Sophie Scott, UK General Manager at Guardant Health. Together, they discuss the role of liquid biopsy technology - a revolutionary blood test used to detect circulating tumour DNA (ctDNA) in cancer patients - and explore its potential in transforming cancer diagnosis and treatment, especially for lung cancer.

This episode covers the evolving partnership between Guardant Health and The Royal Marsden Hospital London, which is at the forefront of piloting liquid biopsy testing in NHS patient pathways. Stephen and Sophie share insights on how this partnership has helped to drive clinical research and improved patient care, speeding up diagnoses and treatment decisions.

Join us for an insightful conversation on the future of liquid biopsy testing, its current applications, and the exciting possibilities for further advancements in genomics.

Visit our website for more resources and updates on genomic-based clinical developments and research. If you've enjoyed this episode, don't forget to share your thoughts and spread the word by tagging the North Thames Genomic Medicine Service on social media